A review conducted by Murdoch University researchers has found the use of inflammatory and oxidative stress biomarkers in psychiatry may have the potential to improve treatment efficacy and aid in the diagnosis of major depression. Currently, remission rates for depression are up to 40 percent, and the assessment and treatment of depression is carried out through a combination of patient interviews, self-reports, and questionnaires. Adrian Lopresti, clinical psychologist and research spokesperson, reported that depression is associated with high levels of inflammation and free radical damage. When the body is inflamed, there is an imbalance in the levels of serotonin, which may influence mood in a way that leads to depression.
Read the entire article here: Biomarkers to finetune depression treatment